# Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma

> **NCT01881789** · PHASE1,PHASE2 · TERMINATED · sponsor: **Amgen** · enrollment: 22 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Oprozomib
- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT01881789
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-10-28
- **Primary completion:** 2019-09-23
- **Final completion:** 2019-09-23
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** A program evaluation identified that the safety profile and pharmacokinetic (PK) characteristics of the formulation used in all oprozomib studies required further optimization and thus enrollment in OPZ003 was halted during dose-escalation.
- **Last updated:** 2022-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01881789

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01881789, "Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01881789. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*